Physician profile
Eric B Thompson
NPI 1972521219
$16,397.33
in general payments reported to CMS, 2019-2025
44 companies · $4,311 in 2025
The $4,311 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,805 · 2020: $1,433 · 2021: $1,781 · 2022: $2,219 · 2023: $1,854 · 2024: $2,995 · 2025: $4,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,131 · Education: $28.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,130.66 |
| Education | $28.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,676.55 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $2,212.65 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Gilead Sciences, INC. | $1,689.72 | 2019-2025 | |
| Janssen Biotech, INC. | $1,467.74 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $918.00 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $658.34 | 2019-2025 | |
| Vivus LLC | $640.61 | 2021-2025 | Pancreaze, Qsymia |
| Ferring Pharmaceuticals INC. | $466.97 | 2019-2024 | Rebyota, Clenpiq |
| Qol Medical, LLC | $463.77 | 2019-2025 | Sucraid, Sucraid |
| Alnylam Pharmaceuticals INC. | $456.86 | 2020-2024 | Givlaari |
| Lilly USA, LLC | $433.24 | 2023-2025 | Omvoh, Zepbound |
| Redhill Biopharma INC. | $373.70 | 2020-2023 | Talicia, Aemcolo |
| Ironwood Pharmaceuticals, INC | $334.73 | 2019-2025 | Linzess |
| Celgene Corporation | $309.32 | 2022-2024 | Zeposia |
| Genzyme Corporation | $281.35 | 2022-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $238.09 | 2020-2021 | |
| Daiichi Sankyo INC. | $202.81 | 2019-2025 | Injectafer |
| Braintree Laboratories, INC. | $186.55 | 2019-2023 | Sutab |
| Regeneron Healthcare Solutions, INC. | $183.64 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $181.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $175.64 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $175.10 | 2019-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $159.14 | 2025 | Zenpep |
| Fresenius Kabi USA, LLC | $153.06 | 2023-2024 | Idacio |
| Intra-Sana Laboratories | $147.85 | 2021-2022 | |
| 3-D Matrix, INC. | $144.10 | 2024 | |
| Ardelyx, INC. | $140.11 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $108.83 | 2024-2025 | Vegzelma, Zymfentra |
| Merck Sharp & Dohme LLC | $93.40 | 2019-2023 | Dificid |
| Organon LLC | $89.80 | 2023-2025 | Hadlima |
| Ipsen Biopharmaceuticals, INC | $82.46 | 2024-2025 | Iqirvo |
| W. L. Gore & Associates, INC. | $82.18 | 2022-2023 | Gore Cardioform Septal Occluder |
| Evoke Pharma, INC. | $81.59 | 2020-2024 | Gimoti |
| Novo Nordisk INC | $55.71 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $55.58 | 2021-2022 | |
| Shionogi INC | $54.58 | 2019 | |
| Medtronic, INC. | $44.46 | 2025 | Interstim |
| Sandoz INC. | $39.27 | 2024-2025 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.08 | 2024 | Cyltezo |
| Dova Pharmaceuticals | $31.01 | 2019 | |
| Mirum Pharmaceuticals, INC. | $22.84 | 2025 | Livmarli |
| Echosens North America, INC. | $17.53 | 2023 | Fibroscan |
| Medtronic USA, INC. | $16.51 | 2019 | |
| Boston Scientific Corporation | $16.11 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.